Nurix Therapeutics, Inc. (NRIX) Financial Analysis & Valuation | Quarter Chart
Nurix Therapeutics, Inc. (NRIX)
NRIXPrice: $17.04
Fair Value: 🔒
🔒score
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the tre... more
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and co... more
Description
Shares
| Market Cap | $1.48B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Arthur T. Sands |
| IPO Date | 2020-07-24 | CAGR | 0.12% |
| Employees | 286 | Website | www.nurixtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.08% | Total Yield | -0.08% |
NRIX chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.85B | P/E Ratio | -5.48 |
| Forward P/E | -5.84 | PEG Ratio | — |
| P/S Ratio | 27.83 | P/B Ratio | 5.28 |
| P/CF Ratio | -9.75 | P/FCF Ratio | -7.35 |
| EPS | $-3.11 | EPS Growth 1Y | 12.86% |
| EPS Growth 3Y | -4.24% | EPS Growth 5Y | 57.21% |
| Revenue Growth 1Y | 27.23% | Gross Margin | -1.39% |
| Operating Margin | -4.39% | Profit Margin | -4.11% |
| ROE | -0.64% | ROA | -0.46% |
| ROCE | -0.58% | Current Ratio | 6.01 |
| Quick Ratio | 6.01 | Cash Ratio | 0.77 |
| Debt/Equity | 0.12 | Interest Coverage | — |
| Altman Z Score | 2.89 | Piotroski Score | 2 |